Gene and Protein Expression Profiles of Anti‐ and Pro‐apoptotic Actions of Dopamine, R‐Apomorphine, Green Tea Polyphenol (−)‐Epigallocatechine‐3‐gallate, and Melatonin

Abstract: Significant evidence has been provided to support the hypothesis that oxidant stress may be responsible for degeneration of dopaminergic neurons in the substantia nigra pars compacta in Parkinson's disease. Dopamine (DA), R‐apomorphine (R‐APO), green tea polyphenol (−)‐epigallocatechine‐3‐gallate (EGCG), and melatonin are neuroprotective and radical scavenger compounds. The aim of this study was to establish the mechanism of the concentration‐dependent neuroprotective and pro‐apoptotic action of these drugs via gene expression and protein determination. cDNA microarrays provide new prospects to study and identify various mechanisms of drug action. We employed this technique for the study reported in this paper. Total RNA was extracted from SH‐SY5Y cells exposed to low neuroprotective and high toxic concentrations of the drugs, followed by synthesis of cDNA, and hybridization to a microarray membrane related to apoptosis, survival, and cell cycle pathways. We demonstrated a concentration and time‐dependent correlation between R‐APO, DA, EGCG, and melatonin in modulation of cell survival/cell death‐related gene pathways. The results were confirmed by quantitative real‐time PCR and protein profiles. Unlike the effects of low concentrations (1‐10 μM), where an antiapoptotic response was manifest, a proapoptotic pattern of gene expression was observed at high toxic concentrations (50‐500 μM) of the antioxidants (e.g., increase in caspases, fas, and gadd45). Our results have provided novel insights into the gene mechanisms involved in both the neuroprotective and proapoptotic activities of neuroprotective drugs. We have shown that DA, R‐APO, EGCG, and melatonin exhibit similar gene expression and protein profiles.

[1]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[2]  Yona Levites,et al.  Involvement of Protein Kinase C Activation and Cell Survival/ Cell Cycle Genes in Green Tea Polyphenol (−)-Epigallocatechin 3-Gallate Neuroprotective Action* , 2002, The Journal of Biological Chemistry.

[3]  F. Herrera,et al.  Protective effect of melatonin in a chronic experimental model of Parkinson’s disease , 2002, Brain Research.

[4]  Wei Wei,et al.  Melatonin blocks rat hippocampal neuronal apoptosis induced by amyloid beta‐peptide 25–35 , 2002, Journal of pineal research.

[5]  M. Naoi,et al.  The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells , 2002, Journal of Neural Transmission.

[6]  C. Hess,et al.  Melatonin protects SHSY5Y neuroblastoma cells from cobalt‐induced oxidative stress, neurotoxicity and increased β‐amyloid secretion , 2001, Journal of pineal research.

[7]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[8]  S. Mandel,et al.  Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurodegeneration , 2001, Journal of neurochemistry.

[9]  Y. Akao,et al.  Transfection‐enforced Bcl‐2 overexpression and an anti‐Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde‐3‐phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N‐methyl(R)salsolinol , 2001, Journal of neurochemistry.

[10]  P. Liebmann,et al.  Prooxidant activity of melatonin promotes fas‐induced cell death in human leukemic Jurkat cells , 2001, FEBS letters.

[11]  S. Mandel,et al.  Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine , 2001, Journal of neurochemistry.

[12]  A. Barzilai,et al.  Is There a Rationale for Neuroprotection Against Dopamine Toxicity in Parkinson's Disease? , 2001, Cellular and Molecular Neurobiology.

[13]  P. Bernardi,et al.  A mitochondrial perspective on cell death. , 2001, Trends in biochemical sciences.

[14]  R. Reiter,et al.  Melatonin as a Pharmacological Agent against Neuronal Loss in Experimental Models of Huntington's Disease, Alzheimer's Disease and Parkinsonism , 1999, Annals of the New York Academy of Sciences.

[15]  S. Mandel,et al.  Apomorphine protects against MPTP‐induced neurotoxicity in mice , 1999, Movement disorders : official journal of the Movement Disorder Society.

[16]  M. M. Esteban,et al.  Melatonin prevents apoptosis induced by 6‐hydroxydopamine in neuronal cells: Implications for Parkinson's disease , 1998, Journal of pineal research.

[17]  H. Baas,et al.  Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. , 1998, Clinical neuropharmacology.

[18]  P Riederer,et al.  Iron in the Parkinsonian substantia nigra. , 1997, Movement disorders : official journal of the Movement Disorder Society.

[19]  T. Ratovitski,et al.  DOPAMINE-INDUCED APOPTOSIS IN HUMAN NEURONAL CELLS: INHIBITION BY NUCLEIC ACIDS ANTISENSE TO THE DOPAMINE TRANSPORTER , 1996, Neuroscience.

[20]  K. Jellinger,et al.  Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. , 1996, Biochimica et biophysica acta.

[21]  A. Barzilai,et al.  Dopamine-induced programmed cell death in mouse thymocytes. , 1995, Biochimica et biophysica acta.

[22]  C. Waters,et al.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.

[23]  C. Waters,et al.  Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis , 1994, Neuroscience.

[24]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[25]  R. Todd Neural development is regulated by classical neurotransmitters: Dopamine D2 receptor stimulation enhances neurite outgrowth , 1992, Biological Psychiatry.

[26]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[27]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Thoenen,et al.  Model experiments on the molecular mechanism of action of 6-hydroxydopamine. , 1971, Molecular pharmacology.

[29]  S. Mandel,et al.  Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. , 2002, Biochemical pharmacology.

[30]  K. Jellinger,et al.  The pathology of Parkinson's disease. , 2001, Advances in neurology.

[31]  S. Mandel,et al.  Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. , 2001, Advances in neurology.

[32]  K. Jellinger Cell death mechanisms in Parkinson's disease , 2000, Journal of Neural Transmission.

[33]  S. Mandel,et al.  Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. , 2000, Journal of neural transmission. Supplementum.

[34]  M. Youdim,et al.  Apomorphine is a potent radical scavenger and protects cultured pheochromocytoma cells from 6-OHDA and H2O2-induced cell death. , 1998, Advances in pharmacology.

[35]  M. Youdim,et al.  Antioxidant and Cytoprotective Properties of Apomorphine , 1998 .

[36]  P. Riederer,et al.  Oxidative stress: free radical production in neural degeneration. , 1994, Pharmacology & therapeutics.

[37]  P. Riederer,et al.  Oxidative stress: a role in the pathogenesis of Parkinson's disease. , 1990, Journal of neural transmission. Supplementum.